Rapt Therapeutics Inc.
13F holders, Q4 2025 (December 31)3holders
0new positions
0sold out
$33.87avg. 13F price*
At the end of Q4 2025, 3 institutions reported holding Rapt Therapeutics Inc. in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 0 sold out. The largest holders were Medicxi Ventures Management (Jersey) Ltd ($94.6M), Column Group LLC ($5.3M) and AJU IB Investment Co., Ltd. ($421K).
- Company
- Rapt Therapeutics Inc.
- CUSIP
- 75382E109
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 9,805 shares sold, net −9,805 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Medicxi Ventures Management (Jersey) Ltd | 11.33% | No change | 2,794,000 | $94.6M |
| Column Group LLC | 6.39% | Reduce -5.9% | 156,270 | $5.3M |
| AJU IB Investment Co., Ltd. | 1.85% | No change | 12,437 | $421K |
"% of holder's portfolio" is RAPT THERAPEUTICS INC's weight in each manager's 13F, not the share of Rapt Therapeutics Inc. the manager owns.